Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ORY.MC
- Price
- 2.78
- Stock movement up
- +0.06 (2.21%)
- Company name
- Oryzon Genomics SA
- Exchange
- (MC ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 176.79M
- Ent value
- 194.16M
- Price/Sales
- 43.04
- Price/Book
- 1.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 84.24
- PEG
- -
- EPS growth
- 14.76%
- 1 year return
- 46.78%
- 3 year return
- 5.76%
- 5 year return
- -1.71%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
ORY.MC does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 43.04 |
| Price to Book | 1.83 |
| EV to Sales | 47.27 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.59M |
| EPS (TTM) | -0.06 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.11M |
| Gross profit (TTM) | 7.12M |
| Operating income (TTM) | -6.27M |
| Net income (TTM) | -4.06M |
| EPS (TTM) | -0.06 |
| EPS (1y forward) | 0.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 173.35% |
| Operating margin (TTM) | -152.70% |
| Profit margin (TTM) | -98.89% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.44M |
| Net receivables | 0.00 |
| Total current assets | 0.00 |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 122.66M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 0.00 |
| Total liabilities | 25.81M |
| Shareholder's equity | 96.85M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -4.19% |
| Return on Assets | -3.31% |
| Return on Invested Capital | -4.19% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.80 |
| Daily high | 2.83 |
| Daily low | 2.75 |
| Daily Volume | 237K |
| All-time high | 5.14 |
| 1y analyst estimate | 6.27 |
| Beta | 0.65 |
| EPS (TTM) | -0.06 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| ORY.MC | S&P500 | |
| Current price drop from All-time high | -45.91% | -12.04% |
| Highest price drop | -72.76% | -56.47% |
| Date of highest drop | 31 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -43.91% | -11.07% |
| Avg time to new high | 341 days | 12 days |
| Max time to new high | 2144 days | 1805 days |
COMPANY DETAILS
Marketcap
176.79M
Marketcap category
Small-cap
Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Employees
46
Website
Investor relations
-
SEC filings
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these ...
March 19, 2025
As European markets navigate the complexities of U.S. trade tariffs and shifting monetary policies, the pan-European STOXX Europe 600 Index recently experienced a decline amid these uncertainties. In ...
March 19, 2025
BIO-Europe Spring 2025Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinic...
March 14, 2025
A non-interventional study published in Frontiers in PsychiatryPsychometric profile characterization of 30 subjects with Phelan-McDermid Syndrome (PMS), defining three distinct subsetsStudy provides c...
March 5, 2025
Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...
March 3, 2025
All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the deve...
February 28, 2025
Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreachPreparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Bor...
February 27, 2025
The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (A...
February 14, 2025
Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...
January 27, 2025
Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),...
January 23, 2025
Next page